Angiostatic and Angiogenic Chemokines in Systemic Sclerosis: An Overview
Authors:
- 26 December 2016
- journal article
- review article
- Published by BMJ in Journal of Scleroderma and Related Disorders
- Vol. 2 (1) , 1-10
Abstract
In systemic sclerosis (SSc), the dysregulation of several molecular pathways seem to have a role in the disease pathogenesis. Either angiogenesis and vasculogenesis are disturbed and impaired, and an imbalance between angiogenic and angiostatic factors may be involved in the genesis and maintenance of vasculopathy. Aberrant immune system activation and function involves both B and T cells, as well as many different chemokines and cytokines. Particularly, chemokines are central to the initiation and maintenance of inflammatory responses as well as angiogenesis and fibrosis. Increased expression of several chemokines as CXCL4 (platelet factor 4), CXCL8 (IL8), CXCL5 (ENA-78), CCL5 (RANTS), CXCL9 (MIG), CCL24, CXCL10 IP-10), CXCL12, CXCL16 (SRPSDX), CCL2 (MCP-1), CCL19 (MIP-3β/ELC), CCL24 (Eotaxin 2), suggests a complex mechanism by which many immune cell types, including T cells, macrophages and neutrophils are recruited to the skin in SSc patients. Many of these chemokines have redundant roles, possibly to ensure recruitment of specific cell types. Several studies have shown a synergistic effect of combinations of these chemokines in cell recruitment, emphasizing the importance of understanding global chemokine expressions. urthermore, chemokines can be detected in peripheral blood compared with cytokines or growth factors. The utility of cytokines as biomarkers has been investigated but longitudinal studies are necessary to clarify their clinical utility for the evaluation of disease activity, therapeutic effects on skin sclerosis or interstitial lung disease and risk stratification of SSc patients. An effective therapeutic agent, able to interfere with complex chemokine networks, is warranted to attenuate perivascular inflammation, dysregulated angiogenesis and the evolution of skin and internal organ fibrosis, is the most ambitious goal for the scientific research of the future.Keywords
This publication has 111 references indexed in Scilit:
- Elevated Levels of CD4+CD25+FoxP3+ T Cells in Systemic Sclerosis Patients Contribute to the Secretion of IL-17 and Immunosuppression DysfunctionPLOS ONE, 2013
- Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosisArthritis Research & Therapy, 2011
- Characterization of CCL19 and CCL21 in rheumatoid arthritisArthritis & Rheumatism, 2011
- Poly(I:C) Drives Type I IFN- and TGFβ-Mediated Inflammation and Dermal Fibrosis Simulating Altered Gene Expression in Systemic SclerosisJournal of Investigative Dermatology, 2010
- Lymphoid chemokines in the CNSJournal of Neuroimmunology, 2010
- Protective effect of eotaxin-2 inhibition in adjuvant-induced arthritisClinical and Experimental Immunology, 2010
- Eotaxin-2/CCL24 and eotaxin-3/CCL26 exert differential profibrogenic effects on human lung fibroblastsAnnals of Allergy, Asthma & Immunology, 2010
- Leukocyte – endothelial interactions in inflammationJournal of Cellular and Molecular Medicine, 2009
- Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patientsArthritis Research & Therapy, 2009
- Orchestrating the orchestrators: chemokines in control of T cell trafficNature Immunology, 2008